Education
About Us
Working with TipRanks
Follow Us
Bone Therapeutics S.A. (GB:0R55)
LSE:0R55
Total Valuation
Bone Therapeutics has a market cap or net worth of €1.44M. The enterprise value is ―.
Market Cap€1.44M
Enterprise Value―
Share Statistics
Bone Therapeutics has 652,862,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding652,862,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Bone Therapeutics’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee0.00
Profits Per Employee-397.33K
Employee Count12
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Bone Therapeutics is ―. Bone Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value―
Price to FCF0.00
Price to Operating Cash Flow-0.09
PEG Ratio―
Income Statement
In the last 12 months, Bone Therapeutics had revenue of 0.00 and earned -4.77M in profits. Earnings per share was -0.02.
Revenue0.00
Gross Profit-196.00K
Operating Income-8.27M
Pretax Income-6.71M
Net Income-4.77M
EBITDA-4.84M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -2.23M and capital expenditures 1.39M, giving a free cash flow of -846.00K billion.
Operating Cash Flow-2.23M
Free Cash Flow-846.00K
Free Cash Flow per Share>-0.01
Dividends & Yields
Bone Therapeutics pays an annual dividend of €0.285, resulting in a dividend yield of ―
Dividend Per Share€0.285
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.68
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)12.58M
Important Dates
Bone Therapeutics upcoming earnings date is Apr 23, 2026, Before Open (Confirmed).
Last Earnings DateOct 22, 2025
Next Earnings DateApr 23, 2026
Ex-Dividend Date―
Financial Position
Bone Therapeutics as a current ratio of ―, with Debt / Equity ratio of -122.91%
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Bone Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate―
Enterprise Valuation
Bone Therapeutics EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Bone Therapeutics has €391.00K in cash and marketable securities with €26.79M in debt, giving a net cash position of -€27.34M billion.
Cash & Marketable Securities€391.00K
Total Debt€26.79M
Net Cash-€27.34M
Net Cash Per Share-€0.04
Tangible Book Value Per Share―
Margins
Gross margin is 100.00%, with operating margin of ―, and net profit margin of ―.
Gross Margin100.00%
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Bone Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―